ANÁLISE DOS ANÁLOGOS DE GLP-1 NA MODULAÇÃO DO COMPORTAMENTO ALIMENTAR E NA RELAÇÃO COM A COMIDA
DOI:
https://doi.org/10.36557/2674-9432.2026v5n8p691-705Palavras-chave:
GLP-1, Comportamento alimentar, Saciedade, Ingestão alimentar, Obesidade.Resumo
A ingestão alimentar é regulada por diversos mecanismos complexos que compõem o controle homeostático e o sistema de recompensa alimentar, no qual o peptídeo semelhante ao glucagon tipo 1 (GLP-1) tem um papel fundamental em enviar sinais de saciedade. Este estudo teve como finalidade analisar os efeitos dos análogos de GLP-1 na modulação do comportamento alimentar, considerando aspectos fisiológicos e comportamentais. Dessa forma, foi conduzida uma revisão integrativa da literatura, com busca na base de dados PubMed (Medline), incluindo artigos originais e revisões publicadas nos últimos cinco anos. A análise dos resultados indica que os fármacos como a liraglutida, semaglutida e tirzepatida promovem uma redução significativa do apetite e da percepção de saciedade. Observou-se ainda que esses análogos influenciam na modulação de aspectos hedônicos, reduzindo o desejo por alimentos altamente palatáveis, e interferindo em comportamentos como o comer emocional e a alimentação por recompensa. A discussão ressalta que, embora apresentem eficácia, as respostas ao medicamento podem variar de acordo com os indivíduos, conforme o padrão alimentar, tornando indispensável o acompanhamento nutricional e multiprofissional. Conclui-se que os análogos de GLP-1 contribuem positivamente para a relação do indivíduo com a comida, mas são necessários mais estudos para avaliar seus efeitos e repercussões nutricionais a longo prazo.
Downloads
Referências
ADAN, R. A. H. et al. Neurobiology driving hyperphagia in obesity: mechanisms and targets. Physiology & Behavior, v. 258, p. 114003, 2023. DOI: https://doi.org/10.1016/j.physbeh.2022.114003.
ALDAWSARI, K. et al. The role of GLP-1 receptor agonists in obesity management: a systematic review. Diabetes Therapy, v. 14, p. 123–138, 2023. DOI: https://doi.org/10.1007/s13300-022-01344-4.
ALDAWSARI, M. et al. The efficacy of GLP-1 analogues on appetite parameters, gastric emptying, food preference and taste among adults with obesity: systematic review of randomized controlled trials. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, v. 16, p. 575–595, 2023. DOI: https://doi.org/10.2147/DMSO.S387116.
AMORIM MOREIRA ALVES, G. et al. Mechanisms of GLP-1 in modulating craving and addiction: neurobiological and translational insights. Medical Sciences, v. 13, n. 3, p. 136, 2025. DOI: https://doi.org/10.3390/medsci13030136.
AOUN, M. et al. The gut–brain axis in regulating appetite and energy balance. Nutrients, v. 16, n. 2, p. 215, 2024. DOI: https://doi.org/10.3390/nu16020215.
BADULESCU, S. et al. Glucagon-like peptide 1 agonist and effects on reward behaviour: a systematic review. Physiology & Behavior, v. 283, p. 114622, 2024. DOI: https://doi.org/10.1016/j.physbeh.2024.114622.
BALANTEKIN, K. N.; KRETZ, M. J.; MIETLICKI-BAASE, E. G. The emerging role of glucagon-like peptide 1 in binge eating. Journal of Endocrinology, v. 262, n. 1, p. e230405, 2024. DOI: https://doi.org/10.1530/JOE-23-0405.
BAUMER-HARRISON, C. et al. From satiety to substance use: neural mechanisms of glucagon-like peptide-1 signaling in appetite and reward. Biological Psychiatry, v. 100, n. 8, p. 840–849, 2026. DOI: https://doi.org/10.1016/j.biopsych.2026.06.015.
BRAGA, L. H. et al. Impact of GLP-1 receptor agonists on energy intake and weight loss. Clinical Nutrition, v. 43, p. 112–120, 2024. DOI: https://doi.org/10.1016/j.clnu.2023.10.012.
CAMPOS, A.; PORT, J. D.; ACOSTA, A. Integrative hedonic and homeostatic food intake regulation by the central nervous system: insights from neuroimaging. Brain Sciences, v. 12, n. 4, p. 431, 2022. DOI: https://doi.org/10.3390/brainsci12040431.
CAMILLERI, M.; LUPIANEZ-MERLY, C. Effects of GLP-1 and other gut hormone receptors on the gastrointestinal tract and implications in clinical practice. American Journal of Gastroenterology, v. 119, n. 6, p. 1028–1037, 2024. DOI: https://doi.org/10.14309/ajg.0000000000002519.
CARUSO, I. et al. Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis. EClinicalMedicine, v. 64, p. 102181, 2023. DOI: https://doi.org/10.1016/j.eclinm.2023.102181.
DAVIES, M. J. et al. Management of hyperglycemia in type 2 diabetes, 2021. Diabetes Care, v. 44, n. 11, p. 2589–2625, 2021. DOI: https://doi.org/10.2337/dci21-0056.
DI FOLCO, U. et al. Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes. Acta Diabetologica, v. 59, n. 10, p. 1287–1294, 2022. DOI: https://doi.org/10.1007/s00592-022-01936-6.
DOVAL-CABALLERO, J. L. E. et al. Potential role of glucagon-like peptide 1 in taste receptors. Frontiers in Endocrinology, v. 16, p. 1683419, 2026. DOI: https://doi.org/10.3389/fendo.2025.1683419.
EDWIGES, M. et al. Nucleus accumbens GLP-1 signaling and its role in reward and metabolic regulation: a systematic review. Frontiers in Neuroanatomy, v. 20, p. 1880560, 2026. DOI: https://doi.org/10.3389/fnana.2026.1880560.
EREN-YAZICIOGLU, C. Y. et al. Can GLP-1 be a target for reward system related disorders? A qualitative synthesis and systematic review analysis of studies on palatable food, drugs of abuse, and alcohol. Frontiers in Behavioral Neuroscience, v. 14, p. 614884, 2021. DOI: https://doi.org/10.3389/fnbeh.2020.614884.
GAO, S. X. et al. GLP-1 at the metabolic-cognitive interface: reward, affect, and memory. Comprehensive Physiology, v. 16, n. 2, p. e70129, 2026. DOI: https://doi.org/10.1002/cph4.70129.
GAO, X. et al. Neural mechanisms of food preference and reward processing: a review of multifaceted influencing factors and intervention strategies. Frontiers in Nutrition, v. 13, p. 1823431, 2026. DOI: https://doi.org/10.3389/fnut.2026.1823431.
HUBER, Y. et al. Gut hormones and appetite regulation: current evidence and future directions. Nutrients, v. 16, n. 5, p. 789, 2024. DOI: https://doi.org/10.3390/nu16050789.
JENSTERLE, M.; JANEŽ, A. Glucagon-like peptide-1 receptor agonists in the treatment of obesity. Hormone Research in Pediatrics, v. 96, n. 6, p. 599–608, 2023. DOI: https://doi.org/10.1159/000521264.
KANU, C. et al. Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: results of a phase 2 study. Diabetes, Obesity and Metabolism, v. 27, n. 12, p. 6988–6998, 2025. DOI: https://doi.org/10.1111/dom.70097.
KARAIVAZOGLOU, K.; AGGELETOPOULOU, I.; TRIANTOS, C. The contribution of the brain-gut axis to the human reward system. Biomedicines, v. 12, n. 8, p. 1861, 2024. DOI: https://doi.org/10.3390/biomedicines12081861.
KOOIJ, S. J. et al. GLP-1 receptor agonists and reward-related eating behavior. International Journal of Obesity, v. 47, p. 234–242, 2023. DOI: https://doi.org/10.1038/s41366-022-01231-2.
KRUG, A. et al. Emotional eating and GLP-1 modulation: recent advances. Appetite, v. 190, p. 107112, 2025. DOI: https://doi.org/10.1016/j.appet.2023.107112.
MARTIN, C. K. et al. Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Nature Medicine, v. 31, n. 9, p. 3141–3150, 2025. DOI: https://doi.org/10.1038/s41591-025-03774-9.
NATALI, A. et al. Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence. Cardiovascular Diabetology, v. 20, n. 1, p. 196, 2021. DOI: https://doi.org/10.1186/s12933-021-01385-5.
NEUVILLE, M. F.; PAQUOT, N.; SCHEEN, A. J. Une nouvelle ère pour les agonistes des récepteurs du glucagon-like peptide-1. Revue Médicale de Liège, v. 78, n. 1, p. 40–45, 2023.
OLIVEIRA, J. S. et al. Nutritional monitoring in patients using GLP-1 receptor agonists. Revista de Nutrição, v. 36, p. e230045, 2023. DOI: https://doi.org/10.1590/1678-9865202336e230045.
PRADO, W. L. et al. Nutritional implications of GLP-1 receptor agonists in obesity treatment. Nutrients, v. 14, n. 9, p. 1823, 2022. DOI: https://doi.org/10.3390/nu14091823.
QIU, J. et al. Exercise modulates food reward: neurobiological mechanisms and implications for weight management. Frontiers in Nutrition, v. 13, p. 1845848, 2026. DOI: https://doi.org/10.3389/fnut.2026.1845848.
RADKHAH, H. et al. The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis. Eating and Weight Disorders, v. 30, n. 1, p. 10, 2025. DOI: https://doi.org/10.1007/s40519-025-01720-9.
RIBEIRO-SILVA, J. C.; TAVARES, C. A. M.; GIRARDI, A. C. C. The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists: a mini-review of the potential mechanisms. Current Opinion in Pharmacology, v. 69, p. 102355, 2023. DOI: https://doi.org/10.1016/j.coph.2023.102355.
RICHARDSON, K. M. et al. The influence of the glucagon-like peptide-1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: a secondary analysis of a randomized controlled trial. Diabetes, Obesity and Metabolism, v. 27, n. 7, p. 3725–3735, 2025. DOI: https://doi.org/10.1111/dom.16395.
RYAN, D. H. Next generation antiobesity medications: setmelanotide, semaglutide, tirzepatide and bimagrumab: what do they mean for clinical practice? Journal of Obesity & Metabolic Syndrome, v. 30, n. 3, p. 196–208, 2021. DOI: https://doi.org/10.7570/jomes21033.
SANTOS, A. F. et al. Dietary intake and micronutrient deficiencies during weight loss treatments. Clinical Nutrition ESPEN, v. 59, p. 45–52, 2024. DOI: https://doi.org/10.1016/j.clnesp.2023.11.010.
SILVA, R. M. et al. Multidisciplinary approach in obesity treatment: role of nutrition. Revista Brasileira de Obesidade, v. 18, n. 2, p. 89–98, 2024.
STUBER, G. D.; SCHWITZGEBEL, V. M.; LÜSCHER, C. The neurobiology of overeating. Neuron, v. 113, n. 11, p. 1680–1693, 2025. DOI: https://doi.org/10.1016/j.neuron.2025.03.010.
SUZUKI, T. et al. Tirzepatide ameliorates eating behaviors regardless of prior exposure to glucagon-like peptide receptor agonists in Japanese patients with type 2 diabetes mellitus. Journal of Diabetes and Its Complications, v. 38, n. 7, p. 108779, 2024. DOI: https://doi.org/10.1016/j.jdiacomp.2024.108779.
THARAKAN, L. et al. A healthy diet intervention alters food preferences and eating behaviours without changing appetite, adipokines or glucose homoeostasis. Journal of Obesity, v. 2026, n. 1, p. e8941754, 2026. DOI: https://doi.org/10.1155/jobe/8941754.
TONGTA, S.; SUNGKAWORN, T.; PATHOMTHONGTAWEECHAI, N. Neurobiological mechanisms and therapeutic potential of glucagon-like peptide-1 receptor agonists in binge eating disorder: a narrative review. International Journal of Molecular Sciences, v. 26, n. 22, p. 10974, 2025. DOI: https://doi.org/10.3390/ijms262210974.
TRONIERI, J. S. et al. Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial. The American Journal of Clinical Nutrition, v. 124, n. 2, p. 101403, 2026. DOI: https://doi.org/10.1016/j.ajcnut.2026.101403.
VAN RUITEN, C. C. et al. Eating behavior modulates the sensitivity to the central effects of GLP-1 receptor agonist treatment: a secondary analysis of a randomized trial. Psychoneuroendocrinology, v. 137, p. 105667, 2022. DOI: https://doi.org/10.1016/j.psyneuen.2022.105667.
VÉNIANT, M. M. et al. Pharmacological advances in GLP-1 receptor agonists. Nature Reviews Endocrinology, v. 20, p. 85–101, 2024. DOI: https://doi.org/10.1038/s41574-023-00872-9.
WANG, J. Y. et al. GLP-1 receptor agonists for the treatment of obesity: role as a promising approach. Frontiers in Endocrinology, v. 14, p. 1085799, 2023. DOI: https://doi.org/10.3389/fendo.2023.1085799.
WEN, J. et al. Semaglutide versus other glucagon-like peptide-1 agonists for weight loss in type 2 diabetes patients: a systematic review and meta-analysis. Cureus, v. 16, n. 9, e69008, 2024. DOI: https://doi.org/10.7759/cureus.69008.
WHITE, G. E. et al. Real-world weight-loss effectiveness of glucagon-like peptide-1 agonists among patients with type 2 diabetes: a retrospective cohort study. Obesity, v. 31, n. 2, p. 537–544, 2023. DOI: https://doi.org/10.1002/oby.23622.
WILDING, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, v. 384, p. 989–1002, 2021. DOI: https://doi.org/10.1056/NEJMoa2032183.
WILLIAMS, D. L. The diverse effects of brain glucagon-like peptide 1 receptors on ingestive behaviour. British Journal of Pharmacology, v. 179, n. 4, p. 571–583, 2022. DOI: https://doi.org/10.1111/bph.15535.
WORLD HEALTH ORGANIZATION (WHO). Obesity and overweight. Geneva: WHO, 2022.
YEH, T. L. et al. Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: a multivariate meta-analysis. PLoS ONE, v. 18, n. 1, e0278685, 2023. DOI: https://doi.org/10.1371/journal.pone.0278685.
YEUNG, A. Y.; TADI, P. Physiology, obesity neurohormonal appetite and satiety control. In: StatPearls. Treasure Island: StatPearls Publishing, 2023.
ZHU, Z. et al. Hedonic eating is controlled by dopamine neurons that oppose GLP-1R satiety. Science, v. 387, n. 6741, eadt0773, 2025. DOI: https://doi.org/10.1126/science.adt0773.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2026 Beatriz Leal Silva Xavier, Emily Vitória Melo de Souza
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Você tem o direito de:
- Compartilhar — copiar e redistribuir o material em qualquer suporte ou formato para qualquer fim, mesmo que comercial.
- Adaptar — remixar, transformar, e criar a partir do material para qualquer fim, mesmo que comercial.
- O licenciante não pode revogar estes direitos desde que você respeite os termos da licença.
De acordo com os termos seguintes:
- Atribuição — Você deve dar o crédito apropriado , prover um link para a licença e indicar se mudanças foram feitas . Você deve fazê-lo em qualquer circunstância razoável, mas de nenhuma maneira que sugira que o licenciante apoia você ou o seu uso.
- Sem restrições adicionais — Você não pode aplicar termos jurídicos ou medidas de caráter tecnológico que restrinjam legalmente outros de fazerem algo que a licença permita.
